The Sp1-DNA-PKcs pathway might be the major effector of DSB repair and radioresistance in GBM cells, raising the possibility of developing small-molecule inhibitors targeting Sp1 or DNA-PKcs, and potentially augmenting the efficacy of GBM therapy as radiosensitizers. This evidence concerns the gene SP1 and glioblastoma.